GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

US FDA Sets May 2023 Decision Date For RSV Vaccine

 
• By Andrew McConaghie
  
new gsk logo and hq
GSK could have its RSV vaccine on the US market by mid-2023 - but is likely to be accompanied by rival Pfizer. • Source: GSK
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip